查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2133952

人工智慧驅動的藥物發現和臨床試驗最佳化市場預測至2034年：按治療領域、部署模式、技術、應用、最終用戶和地區分類的全球分析

AI-Driven Drug Discovery & Clinical Trial Optimization Market Forecasts to 2034 - Global Analysis By Therapeutic Area, Deployment Model, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球人工智慧驅動的藥物發現和臨床試驗最佳化市場預計將在 2026 年達到 69 億美元，並在預測期內以 28.0% 的複合年成長率成長，到 2034 年達到 497 億美元。

人工智慧正在透過將機器學習、預測建模和數據分析整合到藥物研發中，變革藥物發現和臨床試驗流程。利用人工智慧工具可以加速識別有前景的候選藥物、評估分子行為、確定化合物優先順序並簡化臨床前研究。在臨床試驗中，這些解決方案有助於受試者的識別、招募、研究設計、病患監測和試驗結果預測。隨著應用範圍的擴大，製藥和生技公司可以提高營運效率、控制研發成本、最佳化研發決策並縮短患者獲得治療的時間。

根據美國國立衛生研究院（NIH）報告，研究人員開發了一套名為「TrialGPT」的人工智慧系統，旨在將潛在的臨床試驗參與者與ClinicalTrials.gov網站上列出的相關研究進行配對。研究人員使用超過1000組患者信息，並邀請三位臨床醫生對該系統進行了評估，結果表明人工智慧在簡化臨床試驗匹配流程和加快臨床研究入組速度方面具有巨大潛力。

擴大人工智慧在藥物研發的應用

人工智慧在藥物研發領域的日益普及正顯著推動市場成長。製藥公司正利用機器學習和先進的分析技術處理大量的生物訊息，發現潛在的治療化合物，評估分子間的關係，並最佳化研究決策。基於人工智慧的系統簡化了複雜的流程，同時提高了候選化合物的評估和篩檢效率。業界對提高生產力和縮短研發週期的關注，推動了對人工智慧解決方案的投資，進而促使專業平台在藥物發現、臨床前研究和臨床開發等各個環節得到更廣泛的應用。

人們對資料隱私和安全高度關注

隱私和網路安全的挑戰可能會阻礙人工智慧解決方案在藥物研發和臨床研究中的廣泛應用。人工智慧平台通常依賴包含高度敏感的研究資訊、基因組數據和患者特定詳細資訊的大量資料集。保護這些資料集免受資料外洩、濫用和網路威脅需要大量投資和嚴格的監管合規。這些要求會增加部署成本和複雜性。此外，出於對保護製藥公司機密資訊和臨床數據的擔憂，一些機構可能會對將人工智慧技術整合到其整體研發活動中持謹慎態度。

擴大人工智慧在臨床試驗的應用

人工智慧在臨床研究領域的日益普及為市場拓展創造了巨大的機會。人工智慧技術可以輔助受試者識別、招募、研究中心選擇、試驗設計、監控和臨床數據評估。透過應對營運挑戰並簡化試驗流程，這些解決方案能夠提高研發效率。更便捷地取得醫療資料集和進階分析平台也提升了人工智慧技術的應用潛力。隨著製藥公司尋求更快、更有效的臨床研發方法，人工智慧驅動的試驗最佳化技術有望在多個治療領域和研究階段中得到更廣泛的應用。

監管不確定性和不斷演變的人工智慧管治

模糊且不斷變化的監管要求可能會限制人工智慧在藥物研發領域的應用。全球監管機構持續制定人工智慧工具檢驗、演算法輸出評估、資料管理以及軟體可靠性保障的標準。各國監管規定的差異將進一步加劇全球部署的複雜性，並增加合規負擔。監管預期頻繁的變化可能迫使企業更新其檢驗流程和技術基礎設施。這些因素可能導致更長的應用週期、更高的監管成本，並使製藥公司對大力投資人工智慧驅動的研發平台猶豫不決。

新型冠狀病毒（COVID-19）的影響：

新冠疫情加速了藥物研發領域對人工智慧的需求，因為它迫切需要快速發現新的治療方法並最佳化臨床試驗流程。人工智慧技術被用於藥物濫用預防、分子分析、標靶識別以及大量生物醫學資訊的評估。在臨床研究中，數位資料擷取、遠端監測和分散式試驗的日益普及推動了人工智慧解決方案的廣泛應用。因此，疫情凸顯了先進計算技術在藥物發現中的價值，並激發了業界對人工智慧的興趣，以期提高研究和臨床試驗的速度、效率和規範性。

在預測期內，腫瘤學領域預計將佔據最大的市場佔有率。

在預測期內，腫瘤領域預計將佔據最大的市場佔有率。該領域尤其適合人工智慧應用，因為它涉及龐大且多樣化的資料集，涵蓋基因組資訊、診斷圖像、病理數據、患者記錄和臨床研究等。人工智慧技術可以改善藥物標靶發現、化合物評估、患者篩選、臨床實驗參與者招募、合格篩檢以及臨床結果評估。隨著癌症治療研發日益複雜，對高效研究方法的需求不斷成長，這促使人工智慧進一步融入以腫瘤學為重點的藥物和臨床研發活動中。

在預測期內，生技公司板塊預計將呈現最高的複合年成長率。

在預測期內，生技公司板塊預計將呈現最高的成長率。這些公司正在將人工智慧應用於治療標靶發現、分子設計、藥物篩檢、生物標記分析和臨床研究等領域。專注於開發新型療法並提高研究效率，正在推動人工智慧技術的進一步應用。靈活的營運結構以及與科技公司和研究機構的合作也進一步加速了人工智慧的普及。對創新療法計畫的投入增加，預計將加速人工智慧在整個生物技術研發過程中的應用。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其成熟的製藥和生物技術產業基礎。先進的醫療保健體系、大量的研發投入、豐富的臨床數據資源以及人工智慧的日益普及，共同鞏固了該地區的主導地位。製藥公司、生技組織、科技公司和學術機構之間的夥伴關係進一步加速了創新。有利的法規環境和對人工智慧驅動的醫療保健技術不斷成長的投資也在推動人工智慧技術的應用，使該地區的機構能夠更廣泛地將人工智慧融入整個藥物研發流程中。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率。製藥活動的活性化、醫療技術投資的成長、數位化能力的提升以及人工智慧應用的廣泛普及，正在推動該地區的成長。各國政府和產業相關人員也積極推動以技術為導向的研發和藥物開發計畫。該地區龐大的患者群體和不斷擴展的臨床研究生態系統為人工智慧的應用提供了更多機會。製藥公司、生技公司、學術機構和人工智慧技術公司之間的夥伴關係有望加速人工智慧在整個藥物開發流程中的應用。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要參與者（最多3家公司）的SWOT分析
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球人工智慧驅動的藥物發現和臨床試驗最佳化市場：按治療領域分類

  • 腫瘤學
  • 神經病學
  • 心血管疾病
  • 感染疾病
  • 罕見疾病和孤兒疾病

第6章：全球人工智慧驅動的藥物發現和臨床試驗最佳化市場：按部署模式分類

  • 基於雲端的解決方案
  • 本地部署解決方案
  • 混合解決方案

第7章 全球人工智慧驅動的藥物發現和臨床試驗最佳化市場：按技術分類

  • 機器學習和深度學習
  • 自然語言處理（NLP）
  • 電腦視覺
  • 強化學習
  • 預測分析

第8章：全球人工智慧驅動的藥物發現和臨床試驗最佳化市場：按應用領域分類

  • 藥物發現
  • 臨床前開發
  • 臨床試驗設計與最佳化
  • 受試者的招募與維護
  • 藥物安全監測和安全監督

第9章 全球人工智慧驅動的藥物發現和臨床試驗最佳化市場：按最終用戶分類

  • 製藥公司
  • 生技公司
  • 受託研究機構（CRO）
  • 學術研究機構
  • 監管機構

第10章：全球人工智慧驅動的藥物發現和臨床試驗最佳化市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Exscientia
  • Insilico Medicine
  • Recursion Pharmaceuticals
  • BenevolentAI
  • Schrodinger
  • Atomwise
  • Tempus AI
  • Saama Technologies
  • Unlearn
  • Pfizer
  • Roche
  • Novartis
  • AstraZeneca
  • Sanofi
  • Merck
  • XtalPi
  • Isomorphic Labs
  • PhaseV
Product Code: SMRC39631

According to Stratistics MRC, the Global AI-Driven Drug Discovery & Clinical Trial Optimization Market is accounted for $6.9 billion in 2026 and is expected to reach $49.7 billion by 2034 growing at a CAGR of 28.0% during the forecast period. Artificial intelligence is reshaping drug discovery and clinical trial processes by integrating machine learning, predictive modeling, and data analytics into pharmaceutical development. AI tools can accelerate the identification of potential drug candidates, assess molecular behavior, prioritize compounds, and streamline preclinical research. During clinical trials, these solutions assist with participant identification, recruitment, protocol planning, patient monitoring, and forecasting trial outcomes. Increasing implementation allows pharmaceutical and biotechnology organizations to enhance operational efficiency, control research expenses, strengthen development decisions, and shorten the path toward bringing new treatments to patients.

According to the U.S. National Library of Medicine (NIH), researchers developed TrialGPT, an AI system designed to match potential clinical-trial participants with relevant studies listed on ClinicalTrials.gov. The researchers evaluated the system against three clinicians across more than 1,000 patient-criterion pairs, demonstrating the potential of AI to streamline trial matching and support faster clinical research enrollment.

Market Dynamics:

Driver:

Increasing adoption of artificial intelligence in pharmaceutical research

Rising implementation of artificial intelligence within pharmaceutical research is significantly supporting market growth. Drug developers are adopting machine learning and advanced analytical technologies to process extensive biological information, discover potential therapeutic compounds, assess molecular relationships, and strengthen research decisions. AI-based systems can simplify complex workflows while enabling more efficient candidate evaluation and screening. The industry's focus on improving productivity and shortening development processes is encouraging greater investment in artificial intelligence solutions, consequently expanding the use of specialized platforms throughout drug discovery, preclinical research, and clinical development activities.

Restraint:

High data privacy and security concerns

Privacy and cybersecurity challenges can limit the expansion of AI-based solutions across drug development and clinical research. Artificial intelligence platforms often depend on extensive datasets containing confidential research information, genomic records, and sensitive patient details. Protecting these datasets against breaches, unauthorized use, and cyber threats requires substantial investment and strict regulatory compliance. Such requirements can raise deployment expenses and complicate implementation. Furthermore, concerns about safeguarding proprietary pharmaceutical information and clinical data may make certain organizations cautious about integrating AI technologies throughout their research and development activities.

Opportunity:

Expansion of AI applications in clinical trials

Growing implementation of artificial intelligence throughout clinical research creates substantial opportunities for market expansion. AI technologies can support participant identification, recruitment, site selection, study planning, monitoring, and clinical data evaluation. By addressing operational challenges and streamlining trial activities, these solutions can improve development efficiency. The growing accessibility of healthcare datasets and sophisticated analytics platforms is also strengthening adoption potential. As drug developers increasingly pursue faster and more effective clinical development approaches, opportunities for AI-enabled trial optimization technologies are expected to expand across multiple therapeutic fields and research phases.

Threat:

Regulatory uncertainty and evolving ai governance

Unclear and evolving regulatory requirements could restrict the growth of AI applications in pharmaceutical development. Authorities worldwide continue establishing standards for validating artificial intelligence tools, assessing algorithmic outputs, managing data, and ensuring software reliability. Variations between national regulations can further complicate global deployment and increase compliance burdens. Frequent changes to regulatory expectations may also force companies to update validation procedures and technology infrastructure. These factors can extend implementation timelines, raise regulatory costs, and make pharmaceutical organizations more cautious about committing substantial investments to AI-enabled research and clinical development platforms.

Covid-19 Impact:

COVID-19 accelerated demand for artificial intelligence in pharmaceutical research by creating an urgent requirement for rapid therapeutic discovery and more flexible clinical trial processes. AI technologies were applied to drug repurposing, molecular analysis, target identification, and evaluation of extensive biomedical information. Clinical research increasingly incorporated digital data collection, remote monitoring, and decentralized trial practices, supporting wider use of AI-enabled solutions. The pandemic therefore highlighted the value of advanced computational technologies in drug development, increasing industry interest in AI for improving research speed, efficiency, and clinical trial execution.

The oncology segment is expected to be the largest during the forecast period

The oncology segment is expected to account for the largest market share during the forecast period. The field involves large, diverse datasets encompassing genomic information, diagnostic imaging, pathology, patient records, and clinical research, making it particularly suitable for artificial intelligence applications. AI technologies can enhance drug target discovery, compound evaluation, patient selection, trial recruitment, eligibility screening, and clinical outcome assessment. Increasing complexity in cancer treatment development and the demand for efficient research approaches are encouraging greater integration of AI across oncology-focused pharmaceutical and clinical development activities.

The biotechnology firms segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biotechnology firms segment is predicted to witness the highest growth rate. They are adopting artificial intelligence for applications including therapeutic target discovery, molecular design, drug screening, biomarker analysis, and clinical research. Their emphasis on developing novel treatments while improving research efficiency encourages greater use of AI technologies. Flexible operating structures and partnerships with technology companies and research organizations further facilitate adoption. Growing investment in innovative therapeutic programs is expected to accelerate the deployment of AI throughout biotechnology research and development processes.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, benefiting from a well-established pharmaceutical and biotechnology landscape. Advanced healthcare systems, significant research investments, extensive clinical data resources, and growing implementation of artificial intelligence contribute to regional leadership. Partnerships between drug developers, biotechnology organizations, technology companies, and academic institutions further accelerate innovation. Supportive regulatory developments and increasing investment in AI-powered healthcare technologies also facilitate adoption, enabling organizations across the region to integrate artificial intelligence more extensively throughout pharmaceutical research and clinical development.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR. Rising pharmaceutical activity, greater investment in healthcare technology, expanding digital capabilities, and increasing implementation of AI are supporting regional development. Governments and industry participants are also advancing technology-focused research and drug development initiatives. The region's extensive patient base and expanding clinical research ecosystem provide additional opportunities for AI applications. Partnerships among drug manufacturers, biotechnology organizations, academic institutions, and AI technology companies are expected to accelerate adoption across pharmaceutical development.

Key players in the market

Some of the key players in AI-Driven Drug Discovery & Clinical Trial Optimization Market include Exscientia, Insilico Medicine, Recursion Pharmaceuticals, BenevolentAI, Schrodinger, Atomwise, Tempus AI, Saama Technologies, Unlearn, Pfizer, Roche, Novartis, AstraZeneca, Sanofi, Merck, XtalPi, Isomorphic Labs and PhaseV.

Key Developments:

In January 2026, AstraZeneca entered a strategic collaboration with CSPC Pharmaceuticals to expand its weight management and metabolic disease pipeline, reflecting the pharmaceutical industry's growing focus on long-acting therapies designed to address obesity and type 2 diabetes. The collaboration spans across eight development programs and pairs AstraZeneca's global development and commercialization capabilities with CSPC's AI-driven peptide discovery and sustained-release dosing technologies.

In December 2025, Pfizer Inc. announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited, a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight management.

In May 2025, Novartis has signed a strategic agreement with Shanghai Pharma to help sell the Swiss company's mature ophthalmic products in China. Novartis will leverage Shanghai Pharma's omni-channel integrated marketing services and broad market coverage capabilities to accelerate the reach of some Novartis drugs for ocular infections and glaucoma in smaller territories not currently targeted by Novartis.

Therapeutic Areas Covered:

  • Oncology
  • Neurology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Rare & Orphan Diseases

Deployment Models Covered:

  • Cloud-Based Solutions
  • On-Premises Solutions
  • Hybrid Solutions

Technologies Covered:

  • Machine Learning & Deep Learning
  • Natural Language Processing (NLP)
  • Computer Vision
  • Reinforcement Learning
  • Predictive Analytics

Applications Covered:

  • Drug Discovery
  • Preclinical Development
  • Clinical Trial Design & Optimization
  • Patient Recruitment & Retention
  • Pharmacovigilance & Safety Monitoring

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Regulatory Agencies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market, By Therapeutic Area

  • 5.1 Oncology
  • 5.2 Neurology
  • 5.3 Cardiovascular Diseases
  • 5.4 Infectious Diseases
  • 5.5 Rare & Orphan Diseases

6 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market, By Deployment Model

  • 6.1 Cloud-Based Solutions
  • 6.2 On-Premises Solutions
  • 6.3 Hybrid Solutions

7 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market, By Technology

  • 7.1 Machine Learning & Deep Learning
  • 7.2 Natural Language Processing (NLP)
  • 7.3 Computer Vision
  • 7.4 Reinforcement Learning
  • 7.5 Predictive Analytics

8 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market, By Application

  • 8.1 Drug Discovery
  • 8.2 Preclinical Development
  • 8.3 Clinical Trial Design & Optimization
  • 8.4 Patient Recruitment & Retention
  • 8.5 Pharmacovigilance & Safety Monitoring

9 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market, By End User

  • 9.1 Pharmaceutical Companies
  • 9.2 Biotechnology Firms
  • 9.3 Contract Research Organizations (CROs)
  • 9.4 Academic & Research Institutes
  • 9.5 Regulatory Agencies

10 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Exscientia
  • 13.2 Insilico Medicine
  • 13.3 Recursion Pharmaceuticals
  • 13.4 BenevolentAI
  • 13.5 Schrodinger
  • 13.6 Atomwise
  • 13.7 Tempus AI
  • 13.8 Saama Technologies
  • 13.9 Unlearn
  • 13.10 Pfizer
  • 13.11 Roche
  • 13.12 Novartis
  • 13.13 AstraZeneca
  • 13.14 Sanofi
  • 13.15 Merck
  • 13.16 XtalPi
  • 13.17 Isomorphic Labs
  • 13.18 PhaseV

List of Tables

  • Table 1 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Therapeutic Area (2023-2034) ($MN)
  • Table 3 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 4 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Neurology (2023-2034) ($MN)
  • Table 5 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 6 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 7 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Rare & Orphan Diseases (2023-2034) ($MN)
  • Table 8 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Deployment Model (2023-2034) ($MN)
  • Table 9 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Cloud-Based Solutions (2023-2034) ($MN)
  • Table 10 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By On-Premises Solutions (2023-2034) ($MN)
  • Table 11 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Hybrid Solutions (2023-2034) ($MN)
  • Table 12 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Technology (2023-2034) ($MN)
  • Table 13 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Machine Learning & Deep Learning (2023-2034) ($MN)
  • Table 14 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Natural Language Processing (NLP) (2023-2034) ($MN)
  • Table 15 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Computer Vision (2023-2034) ($MN)
  • Table 16 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Reinforcement Learning (2023-2034) ($MN)
  • Table 17 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Predictive Analytics (2023-2034) ($MN)
  • Table 18 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Application (2023-2034) ($MN)
  • Table 19 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Drug Discovery (2023-2034) ($MN)
  • Table 20 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Preclinical Development (2023-2034) ($MN)
  • Table 21 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Clinical Trial Design & Optimization (2023-2034) ($MN)
  • Table 22 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Patient Recruitment & Retention (2023-2034) ($MN)
  • Table 23 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Pharmacovigilance & Safety Monitoring (2023-2034) ($MN)
  • Table 24 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By End User (2023-2034) ($MN)
  • Table 25 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 26 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Biotechnology Firms (2023-2034) ($MN)
  • Table 27 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
  • Table 28 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 29 Global AI-Driven Drug Discovery & Clinical Trial Optimization Market Outlook, By Regulatory Agencies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.